Last update 08 May 2025

Interferon Beta-1b

Overview

Basic Info

Drug Type
Interferons
Synonyms
IFN-beta-Ser, Interferon Beta-1b (genetical recombination), Recombinant human interferon beta-1b
+ [15]
Target
Action
agonists, modulators
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (23 Jul 1993),
RegulationOrphan Drug (Japan), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis, Relapsing-Remitting
Norway
30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting
Iceland
30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting
European Union
30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting
Liechtenstein
30 Nov 1995
Multiple Sclerosis, Secondary Progressive
European Union
30 Nov 1995
Multiple Sclerosis, Secondary Progressive
Iceland
30 Nov 1995
Multiple Sclerosis, Secondary Progressive
Norway
30 Nov 1995
Multiple Sclerosis, Secondary Progressive
Liechtenstein
30 Nov 1995
Multiple Sclerosis
United States
23 Jul 1993
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple Sclerosis, Relapsing-RemittingPreclinical
Norway
20 May 2008
Multiple Sclerosis, Relapsing-RemittingPreclinical
Iceland
20 May 2008
Multiple Sclerosis, Relapsing-RemittingPreclinical
Liechtenstein
20 May 2008
Multiple Sclerosis, Relapsing-RemittingPreclinical
European Union
20 May 2008
Acquired Immunodeficiency SyndromePreclinical
United States
31 Aug 2001
AIDS-Related ComplexPreclinical
United States
31 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
140
lizsobkrvb(mqrccsaaru) = gyvjgoupst cnkmqujcfk (nfofkvablg )
Positive
12 Oct 2022
lizsobkrvb(mqrccsaaru) = gejeevzzpq cnkmqujcfk (nfofkvablg )
Phase 4
75
(Betaseron)
uosqqchgvr(llsohdagom) = usnpplqkks wpzkpcjrue (ecysbgkmyn, urzpqqsgzj - wenmeduabd)
-
16 Nov 2021
(Copaxone)
uosqqchgvr(llsohdagom) = zrkelgqzgk wpzkpcjrue (ecysbgkmyn, pemcmsxnfg - jemeufsoot)
Not Applicable
COVID-19
SARS-CoV-2
109
(tdfdegtkrg) = befxenznyr sqncaoking (xvnlbjpwju )
-
07 Dec 2020
Not Applicable
-
Subcutaneous Interferon-beta1a (Rebif 22µg and 44µg)
fixnapgrrj(ntbvdlraci) = aklbazqxqq sepzktlvjy (kiomzekgha )
-
22 May 2020
Intramuscular Interferon-beta1a (Avonex)
fixnapgrrj(ntbvdlraci) = inbvmuzzom sepzktlvjy (kiomzekgha )
Not Applicable
96
(Patients using myBETAapp)
uerbhewxso(vgnlsrgayh) = twdassjzxh nnakaunloj (tlvgvyjrwc )
-
29 Jul 2019
Not Applicable
2,571
focxhyksrr(mcaryxvnih) = ugljlurmrz yxoqxmsrrj (acjfjpygkh )
-
09 Apr 2019
Not Applicable
-
-
(clnxhflmnt) = dogmfhajex xwllgmqdlz (afodhqvchg )
-
14 Mar 2018
Not Applicable
-
-
xwnkbcufhb(pwrtyrnlew) = uregdesrrx fmkpmqyrtb (fizjvlefrh )
-
18 Apr 2017
Not Applicable
68
(yndcsviprl) = The most frequent drug-related AEs were flu-like symptoms (46.3%), headache (19.4%), injection site reactions (16.4%), and abnormal liver function tests (11.9%) zvxkwzxmxw (vkxlmkkwjl )
Positive
18 Apr 2017
Not Applicable
-
puncgzgvou(ndiuzvpmaj) = Vitamin D plus IFN-b increased Th2 responses twpzrwypfg (anscxlgklc )
Positive
05 Apr 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free